Published in Leuk Lymphoma on June 01, 2005
Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev (2009) 1.90
3D microchannel co-culture: method and biological validation. Integr Biol (Camb) (2010) 1.13
Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood (2015) 1.04
Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance. J Histochem Cytochem (2008) 0.98
Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. Gynecol Oncol (2010) 0.96
Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. Oncotarget (2015) 0.85
In vitro model of metastasis to bone marrow mediates prostate cancer castration resistant growth through paracrine and extracellular matrix factors. PLoS One (2012) 0.85
Neovascular niche for human myeloma cells in immunodeficient mouse bone. PLoS One (2012) 0.81
Cell Trafficking in Multiple Myeloma. Open J Hematol (2012) 0.79
Surface-tension driven open microfluidic platform for hanging droplet culture. Lab Chip (2016) 0.75
Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow. BMC Cancer (2015) 0.75
ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses. J Biol Chem (2003) 1.43
Interferon-induced exonuclease ISG20 exhibits an antiviral activity against human immunodeficiency virus type 1. J Gen Virol (2005) 1.27
TRIM22 E3 ubiquitin ligase activity is required to mediate antiviral activity against encephalomyocarditis virus. J Gen Virol (2009) 1.25
The viral RNA recognition sensor RIG-I is degraded during encephalomyocarditis virus (EMCV) infection. Virology (2009) 1.19
Altered memory capacities and response to stress in p300/CBP-associated factor (PCAF) histone acetylase knockout mice. Neuropsychopharmacology (2007) 1.18
TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements. J Virol (2011) 1.16
TRIM22 inhibits influenza A virus infection by targeting the viral nucleoprotein for degradation. J Virol (2013) 1.08
ISG20, an actor of the innate immune response. Biochimie (2007) 0.99
Identification of interferon-beta-stimulated genes that inhibit angiogenesis in vitro. J Interferon Cytokine Res (2008) 0.94
Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Lett (2002) 0.89
Expression of the IFN-inducible p53-target gene TRIM22 is down-regulated during erythroid differentiation of human bone marrow. Leuk Res (2007) 0.88
The exonuclease ISG20 mainly localizes in the nucleolus and the Cajal (Coiled) bodies and is associated with nuclear SMN protein-containing complexes. J Cell Biochem (2006) 0.85
Regulation of the interferon-inducible p53 target gene TRIM22 (Staf50) in human T lymphocyte activation. J Interferon Cytokine Res (2007) 0.84
The exonuclease ISG20 is directly induced by synthetic dsRNA via NF-kappaB and IRF1 activation. Oncogene (2004) 0.84
Hyaluronan, a major non-protein glycosaminoglycan component of the extracellular matrix in human bone marrow, mediates dexamethasone resistance in multiple myeloma. Br J Haematol (2003) 0.84
The human T-cell leukemia virus type 1 oncoprotein tax controls forkhead box O4 activity through degradation by the proteasome. J Virol (2011) 0.83
[Interferon : antiviral mechanisms and viral escape]. Bull Cancer (2003) 0.80
Polyinosinic-polycytidylic acid induces the expression of interferon-stimulated gene 20 in mesangial cells. Nephron Exp Nephrol (2011) 0.79
Expression of interferon-stimulated gene 20 in vascular endothelial cells. Microbiol Immunol (2008) 0.76